The War Against Heart Failure!

Dr. med. Nazha Hamdani
Dept. of Cardiovascular Physiology, Ruhr University Bochum

The development of effective treatments for heart failure with preserved ejection fraction (HFpEF) is currently limited by poor understanding of the underlying pathophysiology. However, it is clear that co-morbid conditions drive myocardial remodeling in HFpEF, promoting a systemic inflammatory state that contributes to endothelial and cardiomyocyte dysfunction, oxidative stress and modulation of diastolic function. Our recent results allowed us to formulate a comprehensive hypothesis describing how inflammation and oxidative stress affect myocardial dysfunction in heart failure (HF) depending on gender and heart regions. Dr. Hamdani will discuss several important issues, including i) identifying the key signaling pathways leading to improved stiffness, and ii) which pathways lead to elevated cGMP, thereby improving CaMKII post-translational modification, cellular distribution of key enzymes in HFpEF, modulation of stress and metabolic signalling and therapeutic options to improve diastolic function.

Wednesday, 26.02.2020
12:00 – 13:00h
Hörsaal Forschungshaus Ost
Ostring 1, Clinical Research Unit, Hörsaal EG